Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model

Chinese Medical Journal

Volumn 121, Issue 21, 2008, Pages 2167-2171

  Wang, Liang ^a   Cai, Shi Rong ^a   Zhang, Chang Hua ^a   He, Yu Long ^a   Zhan, Wen Hua ^a   Wu, Hui ^a   Peng, Jian Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin II type 1 receptor blocker; Angiotensin converting enzyme inhibitor; Lymphangiogenesis; Stomach neoplasms

Indexed keywords

CAPTOPRIL; LOSARTAN; MATRILYSIN; PERINDOPRIL; VALSARTAN; VASCULOTROPIN C; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; STOMACH CANCER; ANIMAL; DISEASE MODEL; DRUG EFFECT; FEMALE; HUMAN; MALE; PATHOLOGY; PATHOPHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LYMPHANGIOGENESIS; MALE; MATRIX METALLOPROTEINASE 7; MICE; MICE, NUDE; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 58149355795     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200811010-00012     Document Type: Article

References (23)

1. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-1790.
2. Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004; 95: 328-333.
3. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; 18: CD006257.
4. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
5. Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991; 196: 280-283.
6. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2: 1139-1147.
7. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67-75.
8. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176-4179.
9. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004; 1: 11-18.
10. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000; 11: 1-6.
11. Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T, Ino K, et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 2004; 90: 1258-1263.
12. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11: 2686-2694.
13. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res 2004; 7: 101-108.
14. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002; 20: 1227-1231.
15. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005; 92: 1247-1252.
16. He Q, Chen J, Lin HL, Hu P, Chen MH. Expression of peroxisome proliferator-activated receptor gamma, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin Med J 2007; 120: 1498-1504.
17. Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2000; 57 Suppl 1: s3-s7.
18. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81: 761-766.
19. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in vitro and murine models. Eur J Surg Oncol 2005; 31: 1042-1050.
20. Kitoh T, Yanai H, Saitoh Y, Nakamura Y, Matsubara Y, Kitoh H, et al. Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer. J Gastroenterol 2004; 39: 434-440.
21. Ajisaka H, Yonemura Y, Miwa K. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer. Hepatogastroenterology 2004; 51: 900-905.
22. Sanz L, Alvarez-Vallina L. The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol Med 2003; 9: 256-262.
23. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.